37,395 Shares in OrthoPediatrics Corp. $KIDS Bought by Nuveen LLC

Nuveen LLC bought a new stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 37,395 shares of the company's stock, valued at approximately $921,000. Nuveen LLC owned approximately 0.15% of OrthoPediatrics at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Northern Trust Corp boosted its stake in OrthoPediatrics by 0.3% during the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company's stock worth $4,492,000 after acquiring an additional 644 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of OrthoPediatrics by 12.1% during the first quarter. Invesco Ltd. now owns 18,349 shares of the company's stock valued at $452,000 after purchasing an additional 1,986 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of OrthoPediatrics by 31.1% during the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock valued at $228,000 after purchasing an additional 2,338 shares during the last quarter. Barclays PLC lifted its holdings in shares of OrthoPediatrics by 12.2% during the fourth quarter. Barclays PLC now owns 28,390 shares of the company's stock valued at $658,000 after purchasing an additional 3,092 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of OrthoPediatrics by 46.8% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,148 shares of the company's stock valued at $348,000 after purchasing an additional 4,508 shares during the last quarter. Institutional investors own 69.05% of the company's stock.

OrthoPediatrics Stock Performance

OrthoPediatrics stock traded up $0.20 during midday trading on Friday, reaching $20.91. 81,868 shares of the company traded hands, compared to its average volume of 194,888. The firm has a market capitalization of $524.21 million, a price-to-earnings ratio of -11.68 and a beta of 1.06. The business has a 50 day moving average of $21.10 and a two-hundred day moving average of $22.03. OrthoPediatrics Corp. has a 12 month low of $16.59 and a 12 month high of $33.14. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.66 and a quick ratio of 3.43.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.06. The business had revenue of $61.08 million during the quarter, compared to analyst estimates of $61.40 million. OrthoPediatrics had a negative net margin of 18.92% and a negative return on equity of 6.36%. OrthoPediatrics has set its FY 2025 guidance at EPS. As a group, research analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Fred Hite bought 5,076 shares of the firm's stock in a transaction on Thursday, August 21st. The stock was acquired at an average cost of $19.41 per share, for a total transaction of $98,525.16. Following the purchase, the chief financial officer owned 213,065 shares in the company, valued at approximately $4,135,591.65. This represents a 2.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 32.70% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on KIDS. Needham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Thursday, May 8th. BTIG Research lowered their target price on shares of OrthoPediatrics from $40.00 to $39.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Piper Sandler lowered their target price on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Citigroup reiterated a "market outperform" rating on shares of OrthoPediatrics in a report on Friday, August 8th. Finally, Wall Street Zen upgraded shares of OrthoPediatrics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, OrthoPediatrics presently has a consensus rating of "Moderate Buy" and an average target price of $34.14.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.